CytoDyn (OTCMKTS:CYDY) and IGM Biosciences (NASDAQ:IGMS) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, risk, institutional ownership, earnings and analyst recommendations.
Valuation & Earnings
This table compares CytoDyn and IGM Biosciences’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|IGM Biosciences||N/A||N/A||-$43.13 million||($4.80)||-14.38|
CytoDyn is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
0.1% of CytoDyn shares are held by institutional investors. Comparatively, 43.3% of IGM Biosciences shares are held by institutional investors. 8.4% of CytoDyn shares are held by company insiders. Comparatively, 79.3% of IGM Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a breakdown of current ratings and target prices for CytoDyn and IGM Biosciences, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
CytoDyn currently has a consensus price target of $4.00, suggesting a potential downside of 42.28%. IGM Biosciences has a consensus price target of $57.00, suggesting a potential downside of 17.40%. Given IGM Biosciences’ higher probable upside, analysts clearly believe IGM Biosciences is more favorable than CytoDyn.
This table compares CytoDyn and IGM Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
IGM Biosciences beats CytoDyn on 7 of the 8 factors compared between the two stocks.
CytoDyn Company Profile
CytoDyn Inc., a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease. The company has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. CytoDyn Inc. is based in Vancouver, Washington.
IGM Biosciences Company Profile
IGM Biosciences, Inc., a biotechnology company, engages in the research and development of engineered Immunoglobulin M (IgM) antibodies for the treatment of cancer patients. The company's lead product candidate is IGM-2323, a bispecific T cell engaging IgM antibody that completed preclinical trials for targeting CD20 and CD3 proteins for the treatment of relapsed/refractory B cell Non-Hodgkin's lymphoma. It also focuses on developing Death Receptor 5 proteins for the treatment of patients with solid and hematologic malignancies; and T cell engagers, receptor cross-linking agonists, and targeted cytokines. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.